AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00788320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 50,000 IU three times a week for 8 weeks
Study NCT00788320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times a week for 8 weeks
Study NCT04576130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator
Description: Implantation of an ICD for secondary prevention
Study NCT04023370 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of primary iliac artery stenosis and/or occlusive lesions
Description: Stent implantation
Study NCT04023370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment of primary iliac artery stenosis and/or occlusive lesions
Description: Stent implantation
Study NCT03198650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib
Study NCT03198650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab
Study NCT03065062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for part 1 of the study will be 100 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered with food.
Study NCT03065062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib will be administered once weekly on the first day for each of the four weeks during the 4-week cycle. The initial dose for part 1 of the study will be 110 mg. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for gedatolisib are required.
Study NCT03321045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]-Df-Trastuzumab
Description: \[89Zr\]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab.
Study NCT03321045 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI Imaging
Description: 5-6 days post injection the patients will undergo PET/MRI imaging.
Study NCT03125070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice and Internet site with links to existing resources
Description: Receive usual care
Study NCT03125070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet, Mobile app and Telehealth Intervention
Description: Receive INSPIRE and survivorship care plan
Study NCT03125070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03125070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04149990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entresto Pill
Description: NO other interventions
Study NCT04149990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entresto Pill
Description: NO other interventions
Study NCT02747004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT02747004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Administered orally
Study NCT02747004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Loperamide
Description: Administered orally
Study NCT02911103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DBS surgery
Description: Unilateral thalamic DBS therapy
Study NCT02911103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Activa Rechargeable System
Description: Used for diagnostic purposes.
Study NCT02203526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy (cycles 1-6)
Study NCT00590174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: stopping clopidogrel at 1 year after DES implantation
Study NCT02203526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEDDI
Description: Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)
Study NCT02203526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (R) given with TEDD and TEDDI every 3 weeks for cycles 1-6 (all arms)
Study NCT00590174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin,Clopidogrel
Description: continue aspirin and clopidogrel 1year after DES
Study NCT02203526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine given via Ommaya reservoir (IT therapy) on days 1 and day 5 of cycles 2-6 (all arms)
Study NCT02203526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEDD
Description: Temozolomide, etoposide, doxil, dexamthasone, (TEDD) given on first cycle (Arm 1-A)
Study NCT02203526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Arms 2, 3 and 4)
Description: Ibrutinib given on day -3 to day -1 on cycle 1 (Arms 2, 3 and 4)
Study NCT02203526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate on days 1 and day 5 of cycles 2-6 (Arm 4)
Study NCT02203526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Arm 1 - Closed with Amendment G)
Description: Ibrutinib given on day -14 to day -1 on cycle 1 (Arm 1)
Study NCT02203526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Arm 4)
Description: Ibrutinib given on days 1-10 for cycles 1-6 (Arm 4)
Study NCT00065676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: 1 or 2 grams of quercetin or placebo will be given while patients undergo 6-hour OGTT
Study NCT00065676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01326156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee arthroplasty
Description: Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
Study NCT00001452 — intervention group
Intervention type: DRUG
Intervention: oCRH
Study NCT00646022 — intervention group
Intervention type: DRUG
Intervention: [18F]-DOPA
Description: 18F-DOPA PET/CT Scan.
Study NCT00004847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ([18F]-DOPA)
Description: is L 3, 4 dihydroxyphenylalanine (L-DOPA) labeled with the radioactive isotope 18F. In general, PPGLs belong to the group of neuroendocrine tumors. This heterogeneous group of tumors takes up amino acids, transforms them into biogenic amines (dopamine and serotonin) by decarboxylation and stores the amines in vesicles. L DOPA is a precursor of catecholamines (dopamine, norepinephrine and epinephrine). Epinephrine conversion to dopamine is catalyzed by the aromatic amino acid decarboxylase. According to previous and current studies, \[18F\]-DOPA PET is highly sensitive and specific for detection of PHEO/PGL67-69. However, there are only a few reports in the literature using \[18F\]-DOPA as a PET agent and particularly for patients with metastatic PPGLs. PET imaging will be done together with either a CT, an MRI or both modalities.
Study NCT00004847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ([18F]-6F-DA)
Description: is an imaging agent developed at the NIH, that may improve specificity and sensitivity in the localization of PPGLs. \[18F\]-6F-DA enters cells via the membrane norepinephrine transporter. Once inside cells, \[18F\]-6F-DA is translocated via the vesicular monoamine transporter into storage vesicles, where the radioactivity is concentrated. After injection of \[18F\]-6F-DA, the much faster disappearance of \[18F\]-6F-DA-derived radioactivity from the bloodstream and non-neuronal cells than from chromaffin cells should enable rapid visualization of PPGLs by PET scanning.
Study NCT01326156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Knee arthroplasty
Description: Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
Study NCT01853579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH >=0.4 and \<4.6 mU/L, no change to dose; TSH >=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).
Study NCT01853579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Study NCT00656149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation of hand function
Description: 6 weeks, 1 hr/day FES-assisted exercise therapy on a workstation, supervised over the Internet.
Study NCT00656149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise therapy
Description: For one hour per day subjects perform range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 min).
Study NCT04624386 — intervention group
Intervention type: OTHER
Intervention: Thiol disulfide level
Description: Venous blood is collected from all subjects and thiol disulfide levels will be determined from the serum samples obtained from the venous blood.
Study NCT02606981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water chlorination by the Flogenic
Description: The chlorine doser delivers a constant amount of chlorine into water as it flows into a holding tank. The water is then piped to public and private taps.
Study NCT02606981 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Active control, vitamin C dosing into water
Description: The control group will receive a vitamin C dosing device that looks identical to the intervention chlorine doser installed in the holding tank that feeds their shared water access point.
Study NCT02192060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test - Using of a suspension containing Triclosan
Description: The participants should have used only the suspension containing Triclosan during 5 days and have stopped with their biofilm control homemade procedures.
Study NCT02192060 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control - Using of a suspension without Triclosan
Description: The participants should have used only the Placebo suspension during 5 days and have stopped with their biofilm control homemade procedures.
Study NCT03139981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for 28 days
Study NCT03139981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo for ASN002 for 28 days
Study NCT03894982 — intervention group
Intervention type: OTHER
Intervention: Group Classes
Description: Family Learning on Asthma Topics classes will aim to emphasize, encourage, and support teaching methods that include standardized instructions. There will be three topics lasting approximately 45 minutes: General Asthma Knowledge; Asthma Triggers, Medications, and Self-Management. These topics were chosen based on the EPR-3 guideline recommendations to ensure the continuity of messaging. Each class size will be approximately 8 persons and will be taught by a Certified Asthma Educator (AE-C) and will be held in the Family Learning Center at the Children's Hospital Colorado. Classes will be taught in both English and Spanish.
Study NCT02003638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Niacin titrated to 6000 mg daily
Study NCT02003638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo provided in the same pill quantity as niacin arm
Study NCT02581046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 3month of the patients
Description: The surgical timing of phacoemulsification is perform at the age of 3 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
Study NCT02581046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 6 month of the patients
Description: The surgical timing of phacoemulsification is perform at the age of 6 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
Study NCT02581046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjunctival dexamethasone and general anesthesia
Description: All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
Study NCT03478475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol (Euro-Pharm International, Canada)
Study NCT03478475 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill (microcrystalline cellulose 66.3%, starch 33.2%, magnesium stearate 0.5%)
Study NCT03764631 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin
Description: Drug
Study NCT03764631 — intervention group
Intervention type: DRUG
Intervention: Dipeptidyl-peptidase 4 (DPP-4) inhibitors
Description: Dipeptidyl-peptidase 4 - Drug
Study NCT00801788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride
Description: Extended release tablet
Study NCT00801788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone hydrochloride
Description: Extended release tablet
Study NCT03299881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Nerve Stimulator (TENS)
Description: The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
Study NCT03299881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet & Exercise
Description: Subjects to be instructed on a healthy 1200 calorie diet.
Study NCT03299881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet & Exercise
Description: Subjects to be instructed on a healthy 1200 calorie diet.
Study NCT03593343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overnight fasting duration
Description: Subjects will adhere to overnight fasting protocol for 6 days
Study NCT01628679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy treatment
Description: Subjects will be given pelvic floor motor control,proprioception and relaxation exercises. This will be with and without the use of external surface Electromyography (EMG) biofeedback. Education will also be given on pain management, female sexual response and vestibulodynia. Subjects will also practice inserting vaginal inserts of graduating diameter into their vaginas, practicing the skills learned in physical therapy sessions.
Study NCT02965183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature measurements
Study NCT01509976 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: triclosan/triclocarban-containing personal care products
Description: Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.
Study NCT03333096 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ocusweep test battery
Description: Ocusweep test battery to measure vision, visual system and cognitive performance including attention~(Comparison of Ocusweep system to conventional neuropsychological test methods)~(With the help of Ocusweep tests, information is obtained about the functioning of the whole visual system - from the ability of the eye to see to the efficiency of the brain to process visual information and the accuracy of eye movements)
Study NCT03333096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neuropsychological test battery
Description: Conventional neuropsychological test battery to measure executive functioning, attention, visuoconstructive abilities and processing speed
Study NCT01309672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: 1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); taken daily
Study NCT01309672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg, oral, 5 mg twice daily
Study NCT01254864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg by mouth each day of a 28 day cycle.
Study NCT01254864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg by mouth twice daily of a 28 day cycle.
Study NCT01254864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 37.5 mg by mouth daily for two weeks followed by a week of rest in a 28 day cycle.
Study NCT01254864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100 mg by mouth each day of a 28 day cycle.
Study NCT04397653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
Study NCT04397653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
Study NCT04397653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
Study NCT02405364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib/Lenalidomide/Dexamethasone
Description: Induction:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Stem Cell harvest: HD Cyclophosphamide Intensification: HD Melphalan Consolidation:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Maintenance: Lenalidomide (13 cycles)
Study NCT04076059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral
Study NCT01106859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zopiclone
Description: 7.5 mg tablet by mouth. Zopiclone is a commonly used hypnotic in Europe that is known to impair driving in the morning 9 hours after dosing.
Study NCT04076059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT04076059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: All participants were required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.
Study NCT04076059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Description: All participants were required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.
Study NCT01106859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem tartrate sublingual tablet
Description: 3.5 mg zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
Study NCT01106859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sublingual tablet)
Description: Placebo matching zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.